A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland

NCT07502560 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

33609

Enrollment

INDUSTRY

Sponsor class

Conditions

Herpes Zoster

Interventions

BIOLOGICAL: Recombinant zoster vaccine
DRUG: Placebo

Sponsor

GlaxoSmithKline

Collaborators

[object Object]
[object Object]